Allelic loss in parathyroid neoplasia can help characterize malignancy

American Journal of Surgical Pathology

Volumn 29, Issue 8, 2005, Pages 1049-1055

  Hunt, Jennifer L ^a   Carty, Sally E ^a   Yim, John H ^a   Murphy, Justin ^a   Barnes, Leon ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Fractional allelic loss; Loss of heterozygosity; Parathyroid adenoma; Parathyroid carcinoma; Parathyroid hyperplasia

Indexed keywords

ALLELE; ARTICLE; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 13Q; CHROMOSOME 1Q; CHROMOSOME 7Q; CLINICAL ARTICLE; CLINICAL FEATURE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; TUMOR SUPPRESSOR GENE;

ADENOMA; CARCINOMA; HUMANS; HYPERPARATHYROIDISM; HYPERPLASIA; LOSS OF HETEROZYGOSITY; NEOPLASM INVASIVENESS; PARATHYROID NEOPLASMS;

EID: 22944485062     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002;17(suppl. 2):N18-N23.
2. Arnold A, Brown MF, Urena P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995;95:2047-2053.
3. Bergenfelz A, Lindblom P, Tibblin S, et al. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial [see comment]. Ann Surg. 2002;236:543-551.
4. Beus KS, Stack BC Jr. Parathyroid carcinoma. Otolaryngol Clin North Am. 2004;37:845-854.
5. Bondeson AG, Bondeson L, Ljungberg O, et al. Fat staining in parathyroid disease. Diagnostic value and impact on surgical strategy: clinicopathologic analysis of 191 cases. Hum Pathol. 1985;16:1255-1263.
6. Carty SE, Roberts MM, Virgi MA, et al. The elevated parathormone level after concise parathyroid exploration for primary sporadic hyperparathyroidism. Surgery. 2002;132:1086-1093.
7. Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89: 5583-5591.
8. Cetani F, Pardi E, Giovannetti A, et al. Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. Clin Endocrinol (Oxf). 2002;56:457-464.
9. Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf). 2004;60:99-106.
10. Chen KT. Fat stain in hyperparathyroidism. Am J Surg Pathol. 1982;6: 191-192.
11. Clayman GL, Gonzalez HE, El-Naggar A, et al. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer. 2004;100:900-905.
12. Clerici T, Brandle M, Lange J, et al. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. World J Surg. 2004;28:187-192.
13. Correa P, Juhlin C, Rastad J, et al. Allelic loss in clinically and screening-detected primary hyperparathyroidism. Clin Endocrinol (Oxf). 2002;56: 113-117.
14. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma rumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330: 757-761.
15. Cryns VL, Yi SM, Tahara H, et al. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosomes Cancer. 1995;13: 9-17.
16. Dotzenrath C, Teh BT, Farnebo F, et al. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab. 1996;81:3194-3196.
17. Ferzli G, Patel S, Graham A, et al. Three new tools for parathyroid surgery: expensive and unnecessary? [see comment] J Am Coll Surg. 2004;198:349-351.
18. Guarda LA. Rapid intraoperative parathyroid hormone testing with surgical pathology correlations: the 'chemical frozen section.' Am J Clin Pathol. 2004;122:704-712.
19. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004;64:7405-7411.
20. Hobbs MR, Pole AR, Pidwirny GN, et al. Hyperparathyroidism-jaw rumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Am J Hum Genet. 1999;64:518-525.
21. Horanyi J, Duffek L, Szlavik R, et al. Parathyroid surgical failures with misleading falls of intraoperative parathyroid hormone levels. J Endocrinol Invest. 2003;26:1095-1099.
22. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40:657-663.
23. Iacobone M, Lumachi F, Favia G. Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol. 2004;88: 223-228.
24. Kasdon EJ, Rosen S, Cohen RB, et al. Surgical pathology of hyperparathyroidism: usefulness of fat stain and problems in interpretation. Am J Surg Pathol. 1981;5:381-384.
25. Khosla S, Melton J, 3rd. Fracture risk in primary hyperparathyroidism [comment]. J Bone Miner Res. 2002;17(suppl 2):103-107.
26. Lo CY, Chan WF, Kung AW, et al. Surgical treatment for primary hyperparathyroidism in Hong Kong: changes in clinical pattern over 3 decades. Arch Surg. 2004;139:77-82.
27. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dialysis Transplant. 2004;15(suppl, 5):V15-V19.
28. Melton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(suppl. 2):N12-N17.
29. Mozes G, Curlee KJ, Rowland CM, et al. The predictive value of laboratory findings in patients with primary hyperparathyroidism. J Am Coll Surg. 2002;194:126-130.
30. Pearce SH, Trump D, Wooding C, et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf). 1996;45:195-200.
31. Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999;86:378-380.
32. Shan L, Yang Q, Nakamura Y, et al. Frequent loss of heterozygosity at 1p36.3 and p73 abnormality in parathyroid adenomas. Mod Pathol. 2001; 14:273-278.
33. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
34. Sidhu S, Neill AK, Russell CF. Long-term outcome of unilateral parathyroid exploration for primary hyperparathyroidism due to presumed solitary adenoma. World J Surg. 2003;27:339-342.
35. Slebos RJ, Umbach DM, Sommer CA, et al. Analytical and statistical methods to evaluate microsatellite allelic imbalance in small amounts of DNA. Lab Invest. 2004;84:649-657.
36. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol. 2003;34:54-64.
37. Streeten EA, Weinstein LS, Norton JA, et al. Studies in a kindred with parathyroid carcinoma. J Clin Endocrinol Metab. 1992;75:362-366.
38. Szabo E, Carling T, Hessman O, et al. Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab. 2002;87: 3961-3965.
39. Szijan I, Orlow I, Dalamon V, et al. Alterations in the retinoblastoma pathway of cell cycle control in parathyroid tumors. Oncol Rep. 2000;7:421-425.
40. Tanaka C, Uchino S, Noguchi S, et al. Biallelic inactivation by somatic mutations of the MEN1 gene in sporadic parathyroid tumors. Cancer Lett. 2002;175:175-179.
41. Valimaki S, Forsberg L, Farnebo LO, et al. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol. 2002;21:727-735.
42. Vestergaard P, Mollerup CL, Frokjaer VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321:598-602.
43. Villablanca A, Farnebo F, Teh BT, et al. Genetic and clinical characterization of sporadic cystic parathyroid tumours. Clin Endocrinol (Oxf). 2002;56:261-269.